655.40
-1.40
(-0.21%)
At close: January 31 at 9:00:18 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 12 | 26 | 26 |
| Avg. Estimate | 3.75B | 3.48B | 14.16B | 14.68B |
| Low Estimate | 3.39B | 3.27B | 13.8B | 13.65B |
| High Estimate | 4.09B | 3.92B | 14.5B | 16.17B |
| Year Ago Sales | 3.43B | 3.15B | 13.12B | 14.16B |
| Sales Growth (year/est) | 9.12% | 10.71% | 7.95% | 3.66% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RGO.F | -- | -- | -- | -- |
| S&P 500 | 10.32% | 10.05% | 13.98% | 13.74% |
Upgrades & Downgrades
| Maintains | Citigroup: Neutral to Neutral | 1/28/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 1/27/2025 |
| Downgrade | UBS: Buy to Neutral | 1/16/2025 |
| Maintains | Citigroup: Neutral to Neutral | 1/14/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 1/10/2025 |
| Maintains | Truist Securities: Buy to Buy | 1/8/2025 |
Related Tickers
1HM.MU Adaptive Biotechnologies Corporation
7.50
+0.43%
1MRNA.MI Moderna, Inc.
39.44
-2.13%
BEAM Beam Therapeutics Inc.
25.92
-4.99%
SANA Sana Biotechnology, Inc.
3.2200
-7.74%
DNA Ginkgo Bioworks Holdings, Inc.
13.36
-3.95%
DWTX Dogwood Therapeutics, Inc.
12.49
-2.12%
CRSP CRISPR Therapeutics AG
41.59
-1.07%
AKRO Akero Therapeutics, Inc.
54.08
-2.31%
VRTX Vertex Pharmaceuticals Incorporated
461.68
+5.31%
MRNA Moderna, Inc.
39.42
-3.95%